Three CRLs later, Outlook says FDA will sign off on its version of Avastin for wet AMD

Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye condition known as wet AMD. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…

Source: Endpoints News